Drugs / Vormatrigine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07505004 | Jan 2026 → Jan 2027 expected | focal epilepsy | Praxis Precision Medicines | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Praxis Precision Medicines | Results Praxis Precision Medicines Provides Vormatrigine Program Update praxismedicines.com ↗
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-01 | Praxis Precision Medicines | Praxis Precision Medicines Provides Vormatrigine Program Update praxismedicines.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vormatrigine | “Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures” NCT07505004 ↗ |
| Known as | Vormatrigina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068317 ↗ |
| Modality | Small molecule | — CHEMBL6068317 ↗ |
| Route | Oral | “Once daily oral” NCT07505004 ↗ |